Warning: mail() has been disabled for security reasons in /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php on line 110

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-content/plugins/bigcontact/BigContact.php on line 43

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-includes/feed-rss2.php on line 8
Inc. (NASDAQ:MGNX) – US Market Buzz http://www.usmarketbuzz.com Nation and Economy Mon, 20 Jul 2020 16:28:22 +0000 en-US hourly 1 https://wordpress.org/?v=4.9.23 Most Active Buzz: MacroGenics, Inc. (NASDAQ:MGNX), AVEO Pharmaceuticals, Inc.(NASDAQ:AVEO), Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) http://www.usmarketbuzz.com/most-active-buzz-macrogenics-inc-nasdaqmgnx-aveo-pharmaceuticals-inc-nasdaqaveo-dicerna-pharmaceuticals-inc-nasdaqdrna-2575 Fri, 19 Dec 2014 14:29:02 +0000 http://www.usmarketbuzz.com/?p=2575 Lakeway, NY — (US MARKET BUZZ) — 12/19/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on MacroGenics, Inc. (NASDAQ:MGNX), AVEO Pharmaceuticals, Inc.(NASDAQ:AVEO), Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

MacroGenics, Inc. (NASDAQ:MGNX)’s shares gained 15.66% to $33.83. The company on Dec. 6 announced the presentation of pre-clinical data for MGD011, a humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART(R)) protein, at the 56th Annual Meeting of the American Society of Hematology (ASH), taking place in San Francisco, CA. These data demonstrate potent T-cell mediated anti-tumor activity in preclinical models.

Should Investors Buy MGNX After The Recent Development? Find Out Here

Liqin Liu, Ph.D., Senior Scientist at MacroGenics, presented a poster titled: MGD011, Humanized CD19 x CD3 DART(R) Protein with Enhanced Pharmacokinetic Properties, Demonstrates Potent T-Cell Mediated Anti-Tumor Activity in Preclinical Models and Durable B-Cell Depletion in Cynomolgus Monkeys Following Once-a-Week Dosing.

AVEO Pharmaceuticals, Inc.(NASDAQ:AVEO)’s shares climbed 14.16% to $0.81. The company on Nov. 11 announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.

Is AVEO Going To Rise or Fall After Today’s Price Action? Find Out Here

Under the terms of the agreement, Ophthotech is obligated to pay AVEO an upfront option fee of $500,000 to investigate tivozanib as a potential treatment for non-oncologic diseases of the eye.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)’s stock gained 13.53% to $15.94. The company on Dec. 17 announced the appointment of Theodore (Ted) T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations. Dr. Ashburn brings 15 years of product and corporate development experience to Dicerna. In this newly-created position, Dr. Ashburn will lead product strategy and operational efforts for the Company’s Dicer substrate short interfering RNAi (DsiRNA) therapeutics.

Can Traders Buy DRNA After The Solid Rally? Get Free Trend Analysis Here

About thenextbigtrade.com

thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.

Disclaimer

The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.

]]>